Latest On Anika Therapeutics, Inc (ANIK):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-13 12:46 EST | News | Anika Therapeutics Inc. (ANIK) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-09 23:58 EST | News | Anika Therapeutics GAAP EPS of -$0.71 misses by $0.37, revenue of $37.9M beats by $0.54M | N/A | |
| 2023-05-08 20:58 EST | News | Anika Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-04-14 07:59 EST | News | Anika Therapeutics inks cooperation deal with Caligan Partners, adds director to board | N/A | |
| 2023-03-24 22:48 EST | News | Anika Therapeutics (ANIK) Presents at the Sidoti Small-Cap Virtual Conference - Slideshow | N/A | |
About Anika Therapeutics, Inc (ANIK):
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, join read more...t resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
General
- Name Anika Therapeutics, Inc
- Symbol ANIK
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 277
- Fiscal Year EndDecember
- IPO Date1993-04-29
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryHealth Care Supplies
- Web URLhttp://www.anikatherapeutics.com
Valuation
- Trailing PE 43
- Forward PE 42.37
- Price/Sales (Trailing 12 Mt.) 4.28
- Price/Book (Most Recent Quarter) 1.91
- Enterprise Value Revenue 3.56
- Enterprise Value EBITDA 60.38
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.18
- Next Year EPS Estimate $0.91
- Next Quarter EPS Estimate $0.03
- Profit Margin -18%
- Operating Margin 1%
- Return on Equity -9%
- Revenue 130.46 million
- Earnings Per Share $0.79
- Revenue Per Share $9.17
- Gross Profit 80.11 million
- Quarterly Earnings Growth 9.8%
Highlights
- Market Capitalization 519.16 million
- EBITDA 14.82 million
- PE Ratio -5.13
- PEG Ratio 3.19
- Analyst Target Price $48
- Book Value Per Share $19.01
Share Statistics
- Shares Outstanding 14.33 million
- Shares Float 12.67 million
- % Held by Insiders 160%
- % Held by Institutions 98.77%
- Shares Short 1.3 million
- Shares Short Prior Month 1.4 million
- Short Ratio 10.47
- Short % of Float 11%
- Short % of Shares Outstanding 9%
Technicals
- Beta 1.19
- 52 Week High $47.48
- 52 Week Low $24.54
- 50 Day Moving Average 36.87
- 200 Day Moving Average 37.71
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Anika Therapeutics, Inc (ANIK) Dividend Calendar:
Anika Therapeutics, Inc (ANIK) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Anika Therapeutics, Inc (ANIK) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Anika Therapeutics, Inc (ANIK) Chart:
Anika Therapeutics, Inc (ANIK) News:
Below you will find a list of latest news for Anika Therapeutics, Inc (ANIK) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Anika Therapeutics, Inc (ANIK) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ANIK Trades:
Anika Therapeutics, Inc (ANIK) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-04 | 8-K (Current report) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-21 | 8-K (Current report) | |
| 2020-09-08 | 8-K (Current report) | |
| 2020-09-08 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-09-08 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-09-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-08-12 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-07 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-06 | 10-Q/A (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-08-05 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-07-30 | 8-K (Current report) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-06-19 | S-8 (Securities to be offered to employees in employee benefit plans) | |
Anika Therapeutics, Inc (ANIK) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Anika Therapeutics, Inc (ANIK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 160%
Institutional Ownership: 9877%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-03 | JOHN B III HENNEMAN | Director | Buy | 9,310.00 | 9,310.00 | | ||
| 2020-09-03 | Stephen Richard | Director | Buy | 9,310.00 | 9,310.00 | | ||
| 2020-07-09 | James Loerop | EVP Business Development | Sell | 1,244.00 | 35.15 | 43,726.60 | 1,756.00 | |
| 2020-07-08 | James Loerop | EVP Business Development | Buy | 3,000.00 | 3,000.00 | | ||
| 2020-04-26 | Cheryl R Blanchard | President, CEO, Director | Buy | 4,231.00 | 11,697.00 | | ||
| 2020-02-26 | RAYMOND J LAND | Director | Sell | 2,700.00 | 42.68 | 115,236.00 | 13,399.00 | |
| 2020-02-26 | Sylvia Cheung | Chief Financial Officer | Buy | 3,000.00 | 50,162.00 | | ||
| 2020-02-26 | Thomas Finnerty | Chief Human Resources Officer | Buy | 3,000.00 | 9,128.00 | | ||
| 2020-02-25 | Jeffery S Thompson | Director | Buy | 4,107.00 | 10,949.00 | | ||
| 2020-02-25 | SUSAN L N VOGT | Director | Buy | 4,107.00 | 11,652.00 | | ||
| 2020-02-25 | Glenn R. Larsen | Director | Buy | 4,107.00 | 11,697.00 | | ||
| 2020-02-25 | RAYMOND J LAND | Director | Buy | 4,107.00 | 16,099.00 | | ||
| 2020-02-25 | Joseph L. Bower | Director | Buy | 4,107.00 | 17,117.00 | | ||
| 2019-11-08 | Sylvia Cheung | Chief Financial Officer | Sell | 20,000.00 | 59.71 | 1,194,200.00 | 47,741.00 | |
| 2019-11-06 | Sylvia Cheung | Chief Financial Officer | Buy | 35,000.00 | 6.36 | 222,600.00 | 71,422.00 | |
| 2019-08-28 | Glenn R. Larsen | Director | Sell | 4,355.00 | 57.21 | 249,149.55 | 7,590.00 | |
| 2019-08-20 | Joseph L. Bower | Director | Sell | 1,994.00 | 55.57 | 110,806.58 | 43,010.00 | |
| 2019-08-08 | Jeffery S Thompson | Director | Sell | 4,843.00 | 56.66 | 274,404.38 | 6,842.00 | |
| 2019-07-29 | RAYMOND J LAND | Director | Sell | 3,000.00 | 55.44 | 166,320.00 | 11,992.00 | |
| 2019-02-28 | Joseph G Darling | President and CEO; Director | Buy | 1,000.00 | 33.20 | 33,200.00 | 22,436.00 | |